|  Sign up!  

scientia

Return to Course Listing

 

 

CME: Metastatic Melanoma: Novel Approaches in Immuno- and Molecularly-Targeted Therapy, Therapeutic Updates, and Best Practices in Involving the Patient in Care

 


Program Description / Statement of Need:

Melanoma is a tumor of the melanocytes whose tissue of origin is primarily the skin, although it may also develop occasionally in the: gastrointestinal, genitourinary, or respiratory tracts; ocular or mucosal tissue; or meninges. It is subcategorized into superficial spreading melanoma (70% of cases), nodular melanoma (15-30%), lentigo maligna melanoma (10%-20%), and acral lentiginous melanoma (5%). Risk factors include a positive personal or family history of melanoma, genetic predisposition, and exposure to ultraviolet light.Diagnosis is made by excisional, incisional, or punch skin biopsy while imaging or indirect ophthalmoscopy may be employed to diagnose uveal or choroidal melanoma.The seventh most common cancer in the U.S., it has an annual incidence of over 76,000.

 

In this online CME self-learning program:

 

Faculty introduction, disclosures

Introduction content: cursory refresher and review

  • Epidemiology: statistics by severity
  • Causes and risk factors
  • Clinical features, presentation, and histopathology
  • Pathogenesis and the role of the immune system

Emerging immuno- and monoclonal therapy in melanoma

  • How has the treatment landscape changed in the last decade, and where is it going?
  • Immunotherapy and monoclonal antibodies vs. conventional cytotoxic chemotherapy: mechanisms of action and impact on biochemical pathways and the cell life cycle
  • Targeted mechanisms of action: which are the targets?
  • Safety profiles: immunotherapy and monoclonal antibodies vs. conventional cytotoxic chemotherapy
  • Other emerging therapies
  • Updates in the recent clinical literature
  • Immunotherapy and monoclonal antibodies in present melanoma treatment guidelines
  • Evaluation of therapeutic outcomes and strategies for involving and educating the patient
  • Barriers to care
  • Best practice: putting it all together
  • Patient case(s)

Summary, conclusions, and best practice recap


 

Target Audience:

The following healthcare professionals: oncologists, dermatologists, and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with malignant melanoma.



Program Objectives:

By the end of the session the participant will be able to:

    • Describe the role of the immune system in cancer and cancer therapy in metastatic melanoma.
    • Distinguish between the different forms of therapy presently approved for metastatic melanoma and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
    • Describe emerging (investigational) therapies for metastatic melanoma
    • Describe the challenges and barriers to care associated with treating patients with metastatic melanoma


    Accreditation:

    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.

     

    Credit Designation: ScientiaCME designates this educational activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.

     

    Pharmacists

     

    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.25 hours (0.125 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-17-046-H01-P.  ACPE Accreditation effective 12/4/17, expires 12/4/19. This is a Knowledge (K)-type activity.



    Release Date: December 04, 2017
    Expiration Date: December 04, 2019

    Faculty: Diwakar Davar MD


    Faculty Disclosure and Resolution of COI:

    As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.

     

    Faculty Disclosure:  Diwakar Davar, MD, Assistant Professor, Melanoma and Phase I Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA has received grants and/or serves as a consultant to Merck and Incyte Pharmaceuticals.

     

    Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, CEO of ScientiaCME has no relevant financial disclosures.

     

    Commercial Support Disclosure: This program is supported by educational grants from Promethius.


    Additional Courses That Are Related To This Course


    Basal Cell Carcinoma (BCC): Therapeutic Updates, Best Practices, and the Role of Personalized Patient Care

    Metastatic Melanoma: Updates from ASCO 2017

     

    Viewing Instructions

     

    PC

    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    MAC
    Mac OS 10.2.8
    Safari
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh

     

    *Required to view Printable PDF Version

     

    Privacy Policy

     

    Instructions:


    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.


    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.


    Download the Presentation (optional)


     

    View the online program

     

    Perform Post-Test


    Complete the Symposium Evaluation and Request CE Certificate



This program is supported by educational grants from Promethius.

 


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.